Free Trial

Wealthquest Corp Buys New Position in Icon Plc (NASDAQ:ICLR)

Icon logo with Medical background

Wealthquest Corp bought a new position in shares of Icon Plc (NASDAQ:ICLR - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,928 shares of the medical research company's stock, valued at approximately $862,000.

A number of other institutional investors have also made changes to their positions in the company. Handelsbanken Fonder AB lifted its position in shares of Icon by 25.3% during the first quarter. Handelsbanken Fonder AB now owns 25,905 shares of the medical research company's stock worth $4,533,000 after purchasing an additional 5,229 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Icon by 22.8% during the first quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock worth $99,000 after purchasing an additional 110 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Icon during the first quarter worth $59,000. GAMMA Investing LLC lifted its position in shares of Icon by 15,701.6% during the first quarter. GAMMA Investing LLC now owns 68,421 shares of the medical research company's stock worth $119,730,000 after purchasing an additional 67,988 shares in the last quarter. Finally, Foyston Gordon & Payne Inc raised its holdings in Icon by 27.3% in the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company's stock valued at $10,845,000 after acquiring an additional 11,089 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Truist Financial cut their price target on shares of Icon from $262.00 to $208.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Citigroup cut their price target on shares of Icon from $290.00 to $215.00 and set a "buy" rating on the stock in a report on Monday, April 7th. JPMorgan Chase & Co. cut shares of Icon from an "overweight" rating to a "neutral" rating and cut their price target for the company from $265.00 to $150.00 in a report on Tuesday, April 29th. The Goldman Sachs Group cut their price target on shares of Icon from $180.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Finally, TD Cowen lowered shares of Icon from a "buy" rating to a "hold" rating and lowered their target price for the company from $254.00 to $157.00 in a research note on Monday, April 14th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $213.08.

Check Out Our Latest Stock Report on ICLR

Icon Stock Performance

Shares of Icon stock traded down $2.19 during trading on Friday, hitting $144.56. 1,212,929 shares of the stock were exchanged, compared to its average volume of 1,113,488. The stock's fifty day moving average is $139.13 and its 200 day moving average is $171.99. The stock has a market cap of $11.67 billion, a PE ratio of 15.75, a P/E/G ratio of 1.80 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.27 and a current ratio of 1.27. Icon Plc has a 12 month low of $125.10 and a 12 month high of $347.72.

Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.17 by $0.02. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.03 billion. Icon had a net margin of 9.25% and a return on equity of 11.46%. The company's quarterly revenue was down 4.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.47 earnings per share. As a group, sell-side analysts anticipate that Icon Plc will post 13.38 EPS for the current year.

Icon Company Profile

(Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Should You Invest $1,000 in Icon Right Now?

Before you consider Icon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list.

While Icon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines